1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Gaucher’s Disease
        1.2.3 Fabry Disease
        1.2.4 Pompe Disease
        1.2.5 Mucopolysaccharidosis VI
        1.2.6 Other
    1.3 Market by Application
        1.3.1 Global Neurometabolic Disorders Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Oral
        1.3.3 Parenteral
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Neurometabolic Disorders Market Perspective (2017-2028)
    2.2 Neurometabolic Disorders Growth Trends by Region
        2.2.1 Neurometabolic Disorders Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Neurometabolic Disorders Historic Market Size by Region (2017-2022)
        2.2.3 Neurometabolic Disorders Forecasted Market Size by Region (2023-2028)
    2.3 Neurometabolic Disorders Market Dynamics
        2.3.1 Neurometabolic Disorders Industry Trends
        2.3.2 Neurometabolic Disorders Market Drivers
        2.3.3 Neurometabolic Disorders Market Challenges
        2.3.4 Neurometabolic Disorders Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Neurometabolic Disorders Players by Revenue
        3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2017-2022)
        3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2017-2022)
    3.2 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
    3.4 Global Neurometabolic Disorders Market Concentration Ratio
        3.4.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2021
    3.5 Neurometabolic Disorders Key Players Head office and Area Served
    3.6 Key Players Neurometabolic Disorders Product Solution and Service
    3.7 Date of Enter into Neurometabolic Disorders Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Neurometabolic Disorders Breakdown Data by Type
    4.1 Global Neurometabolic Disorders Historic Market Size by Type (2017-2022)
    4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2023-2028)
5 Neurometabolic Disorders Breakdown Data by Application
    5.1 Global Neurometabolic Disorders Historic Market Size by Application (2017-2022)
    5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Neurometabolic Disorders Market Size (2017-2028)
    6.2 North America Neurometabolic Disorders Market Size by Type
        6.2.1 North America Neurometabolic Disorders Market Size by Type (2017-2022)
        6.2.2 North America Neurometabolic Disorders Market Size by Type (2023-2028)
        6.2.3 North America Neurometabolic Disorders Market Share by Type (2017-2028)
    6.3 North America Neurometabolic Disorders Market Size by Application
        6.3.1 North America Neurometabolic Disorders Market Size by Application (2017-2022)
        6.3.2 North America Neurometabolic Disorders Market Size by Application (2023-2028)
        6.3.3 North America Neurometabolic Disorders Market Share by Application (2017-2028)
    6.4 North America Neurometabolic Disorders Market Size by Country
        6.4.1 North America Neurometabolic Disorders Market Size by Country (2017-2022)
        6.4.2 North America Neurometabolic Disorders Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Neurometabolic Disorders Market Size (2017-2028)
    7.2 Europe Neurometabolic Disorders Market Size by Type
        7.2.1 Europe Neurometabolic Disorders Market Size by Type (2017-2022)
        7.2.2 Europe Neurometabolic Disorders Market Size by Type (2023-2028)
        7.2.3 Europe Neurometabolic Disorders Market Share by Type (2017-2028)
    7.3 Europe Neurometabolic Disorders Market Size by Application
        7.3.1 Europe Neurometabolic Disorders Market Size by Application (2017-2022)
        7.3.2 Europe Neurometabolic Disorders Market Size by Application (2023-2028)
        7.3.3 Europe Neurometabolic Disorders Market Share by Application (2017-2028)
    7.4 Europe Neurometabolic Disorders Market Size by Country
        7.4.1 Europe Neurometabolic Disorders Market Size by Country (2017-2022)
        7.4.2 Europe Neurometabolic Disorders Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Neurometabolic Disorders Market Size (2017-2028)
    8.2 Asia-Pacific Neurometabolic Disorders Market Size by Type
        8.2.1 Asia-Pacific Neurometabolic Disorders Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Neurometabolic Disorders Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Neurometabolic Disorders Market Share by Type (2017-2028)
    8.3 Asia-Pacific Neurometabolic Disorders Market Size by Application
        8.3.1 Asia-Pacific Neurometabolic Disorders Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Neurometabolic Disorders Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Neurometabolic Disorders Market Share by Application (2017-2028)
    8.4 Asia-Pacific Neurometabolic Disorders Market Size by Region
        8.4.1 Asia-Pacific Neurometabolic Disorders Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Neurometabolic Disorders Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Neurometabolic Disorders Market Size (2017-2028)
    9.2 Latin America Neurometabolic Disorders Market Size by Type
        9.2.1 Latin America Neurometabolic Disorders Market Size by Type (2017-2022)
        9.2.2 Latin America Neurometabolic Disorders Market Size by Type (2023-2028)
        9.2.3 Latin America Neurometabolic Disorders Market Share by Type (2017-2028)
    9.3 Latin America Neurometabolic Disorders Market Size by Application
        9.3.1 Latin America Neurometabolic Disorders Market Size by Application (2017-2022)
        9.3.2 Latin America Neurometabolic Disorders Market Size by Application (2023-2028)
        9.3.3 Latin America Neurometabolic Disorders Market Share by Application (2017-2028)
    9.4 Latin America Neurometabolic Disorders Market Size by Country
        9.4.1 Latin America Neurometabolic Disorders Market Size by Country (2017-2022)
        9.4.2 Latin America Neurometabolic Disorders Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Neurometabolic Disorders Market Size (2017-2028)
    10.2 Middle East & Africa Neurometabolic Disorders Market Size by Type
        10.2.1 Middle East & Africa Neurometabolic Disorders Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Neurometabolic Disorders Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Neurometabolic Disorders Market Share by Type (2017-2028)
    10.3 Middle East & Africa Neurometabolic Disorders Market Size by Application
        10.3.1 Middle East & Africa Neurometabolic Disorders Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Neurometabolic Disorders Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Neurometabolic Disorders Market Share by Application (2017-2028)
    10.4 Middle East & Africa Neurometabolic Disorders Market Size by Country
        10.4.1 Middle East & Africa Neurometabolic Disorders Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Neurometabolic Disorders Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Amicus Therapeutics
        11.1.1 Amicus Therapeutics Company Details
        11.1.2 Amicus Therapeutics Business Overview
        11.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
        11.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2017-2022)
        11.1.5 Amicus Therapeutics Recent Developments
    11.2 ISU Abxis
        11.2.1 ISU Abxis Company Details
        11.2.2 ISU Abxis Business Overview
        11.2.3 ISU Abxis Neurometabolic Disorders Introduction
        11.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2017-2022)
        11.2.5 ISU Abxis Recent Developments
    11.3 JCR Pharmaceuticals
        11.3.1 JCR Pharmaceuticals Company Details
        11.3.2 JCR Pharmaceuticals Business Overview
        11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
        11.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022)
        11.3.5 JCR Pharmaceuticals Recent Developments
    11.4 Biosidus
        11.4.1 Biosidus Company Details
        11.4.2 Biosidus Business Overview
        11.4.3 Biosidus Neurometabolic Disorders Introduction
        11.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2017-2022)
        11.4.5 Biosidus Recent Developments
    11.5 Greenovation Biotech
        11.5.1 Greenovation Biotech Company Details
        11.5.2 Greenovation Biotech Business Overview
        11.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
        11.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2017-2022)
        11.5.5 Greenovation Biotech Recent Developments
    11.6 UAB Proforma
        11.6.1 UAB Proforma Company Details
        11.6.2 UAB Proforma Business Overview
        11.6.3 UAB Proforma Neurometabolic Disorders Introduction
        11.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2017-2022)
        11.6.5 UAB Proforma Recent Developments
    11.7 Dong-A Socio Group
        11.7.1 Dong-A Socio Group Company Details
        11.7.2 Dong-A Socio Group Business Overview
        11.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
        11.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2017-2022)
        11.7.5 Dong-A Socio Group Recent Developments
    11.8 ExSAR Corporation
        11.8.1 ExSAR Corporation Company Details
        11.8.2 ExSAR Corporation Business Overview
        11.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
        11.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2017-2022)
        11.8.5 ExSAR Corporation Recent Developments
    11.9 Lixte Biotechnology
        11.9.1 Lixte Biotechnology Company Details
        11.9.2 Lixte Biotechnology Business Overview
        11.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
        11.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2017-2022)
        11.9.5 Lixte Biotechnology Recent Developments
    11.10 Neuraltus Pharmaceuticals
        11.10.1 Neuraltus Pharmaceuticals Company Details
        11.10.2 Neuraltus Pharmaceuticals Business Overview
        11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
        11.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022)
        11.10.5 Neuraltus Pharmaceuticals Recent Developments
    11.11 Protalix
        11.11.1 Protalix Company Details
        11.11.2 Protalix Business Overview
        11.11.3 Protalix Neurometabolic Disorders Introduction
        11.11.4 Protalix Revenue in Neurometabolic Disorders Business (2017-2022)
        11.11.5 Protalix Recent Developments
    11.12 Pharming Group
        11.12.1 Pharming Group Company Details
        11.12.2 Pharming Group Business Overview
        11.12.3 Pharming Group Neurometabolic Disorders Introduction
        11.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2017-2022)
        11.12.5 Pharming Group Recent Developments
    11.13 Protalix BioTherapeutics
        11.13.1 Protalix BioTherapeutics Company Details
        11.13.2 Protalix BioTherapeutics Business Overview
        11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
        11.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2017-2022)
        11.13.5 Protalix BioTherapeutics Recent Developments
    11.14 Amicus
        11.14.1 Amicus Company Details
        11.14.2 Amicus Business Overview
        11.14.3 Amicus Neurometabolic Disorders Introduction
        11.14.4 Amicus Revenue in Neurometabolic Disorders Business (2017-2022)
        11.14.5 Amicus Recent Developments
    11.15 Biomarin
        11.15.1 Biomarin Company Details
        11.15.2 Biomarin Business Overview
        11.15.3 Biomarin Neurometabolic Disorders Introduction
        11.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2017-2022)
        11.15.5 Biomarin Recent Developments
    11.16 Genzyme
        11.16.1 Genzyme Company Details
        11.16.2 Genzyme Business Overview
        11.16.3 Genzyme Neurometabolic Disorders Introduction
        11.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2017-2022)
        11.16.5 Genzyme Recent Developments
    11.17 Shire
        11.17.1 Shire Company Details
        11.17.2 Shire Business Overview
        11.17.3 Shire Neurometabolic Disorders Introduction
        11.17.4 Shire Revenue in Neurometabolic Disorders Business (2017-2022)
        11.17.5 Shire Recent Developments
    11.18 Greencross
        11.18.1 Greencross Company Details
        11.18.2 Greencross Business Overview
        11.18.3 Greencross Neurometabolic Disorders Introduction
        11.18.4 Greencross Revenue in Neurometabolic Disorders Business (2017-2022)
        11.18.5 Greencross Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Gaucher’s Disease
    Table 3. Key Players of Fabry Disease
    Table 4. Key Players of Pompe Disease
    Table 5. Key Players of Mucopolysaccharidosis VI
    Table 6. Key Players of Other
    Table 7. Global Neurometabolic Disorders Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Neurometabolic Disorders Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Neurometabolic Disorders Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Neurometabolic Disorders Market Share by Region (2017-2022)
    Table 11. Global Neurometabolic Disorders Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Neurometabolic Disorders Market Share by Region (2023-2028)
    Table 13. Neurometabolic Disorders Market Trends
    Table 14. Neurometabolic Disorders Market Drivers
    Table 15. Neurometabolic Disorders Market Challenges
    Table 16. Neurometabolic Disorders Market Restraints
    Table 17. Global Neurometabolic Disorders Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Neurometabolic Disorders Revenue Share by Players (2017-2022)
    Table 19. Global Top Neurometabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2021)
    Table 20. Ranking of Global Top Neurometabolic Disorders Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Neurometabolic Disorders Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Neurometabolic Disorders Product Solution and Service
    Table 24. Date of Enter into Neurometabolic Disorders Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Neurometabolic Disorders Revenue Market Share by Type (2017-2022)
    Table 28. Global Neurometabolic Disorders Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Neurometabolic Disorders Revenue Market Share by Type (2023-2028)
    Table 30. Global Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Neurometabolic Disorders Revenue Share by Application (2017-2022)
    Table 32. Global Neurometabolic Disorders Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Neurometabolic Disorders Revenue Share by Application (2023-2028)
    Table 34. North America Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Neurometabolic Disorders Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Neurometabolic Disorders Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Neurometabolic Disorders Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Neurometabolic Disorders Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Neurometabolic Disorders Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Neurometabolic Disorders Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Neurometabolic Disorders Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Neurometabolic Disorders Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Neurometabolic Disorders Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Neurometabolic Disorders Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Neurometabolic Disorders Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Neurometabolic Disorders Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Neurometabolic Disorders Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Neurometabolic Disorders Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Neurometabolic Disorders Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Neurometabolic Disorders Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Neurometabolic Disorders Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Neurometabolic Disorders Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Neurometabolic Disorders Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Neurometabolic Disorders Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Neurometabolic Disorders Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Neurometabolic Disorders Market Size by Country (2023-2028) & (US$ Million)
    Table 64. Amicus Therapeutics Company Details
    Table 65. Amicus Therapeutics Business Overview
    Table 66. Amicus Therapeutics Neurometabolic Disorders Product
    Table 67. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 68. Amicus Therapeutics Recent Developments
    Table 69. ISU Abxis Company Details
    Table 70. ISU Abxis Business Overview
    Table 71. ISU Abxis Neurometabolic Disorders Product
    Table 72. ISU Abxis Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 73. ISU Abxis Recent Developments
    Table 74. JCR Pharmaceuticals Company Details
    Table 75. JCR Pharmaceuticals Business Overview
    Table 76. JCR Pharmaceuticals Neurometabolic Disorders Product
    Table 77. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 78. JCR Pharmaceuticals Recent Developments
    Table 79. Biosidus Company Details
    Table 80. Biosidus Business Overview
    Table 81. Biosidus Neurometabolic Disorders Product
    Table 82. Biosidus Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 83. Biosidus Recent Developments
    Table 84. Greenovation Biotech Company Details
    Table 85. Greenovation Biotech Business Overview
    Table 86. Greenovation Biotech Neurometabolic Disorders Product
    Table 87. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 88. Greenovation Biotech Recent Developments
    Table 89. UAB Proforma Company Details
    Table 90. UAB Proforma Business Overview
    Table 91. UAB Proforma Neurometabolic Disorders Product
    Table 92. UAB Proforma Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 93. UAB Proforma Recent Developments
    Table 94. Dong-A Socio Group Company Details
    Table 95. Dong-A Socio Group Business Overview
    Table 96. Dong-A Socio Group Neurometabolic Disorders Product
    Table 97. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 98. Dong-A Socio Group Recent Developments
    Table 99. ExSAR Corporation Company Details
    Table 100. ExSAR Corporation Business Overview
    Table 101. ExSAR Corporation Neurometabolic Disorders Product
    Table 102. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 103. ExSAR Corporation Recent Developments
    Table 104. Lixte Biotechnology Company Details
    Table 105. Lixte Biotechnology Business Overview
    Table 106. Lixte Biotechnology Neurometabolic Disorders Product
    Table 107. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 108. Lixte Biotechnology Recent Developments
    Table 109. Neuraltus Pharmaceuticals Company Details
    Table 110. Neuraltus Pharmaceuticals Business Overview
    Table 111. Neuraltus Pharmaceuticals Neurometabolic Disorders Product
    Table 112. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 113. Neuraltus Pharmaceuticals Recent Developments
    Table 114. Protalix Company Details
    Table 115. Protalix Business Overview
    Table 116. Protalix Neurometabolic Disorders Product
    Table 117. Protalix Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 118. Protalix Recent Developments
    Table 119. Pharming Group Company Details
    Table 120. Pharming Group Business Overview
    Table 121. Pharming Group Neurometabolic Disorders Product
    Table 122. Pharming Group Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 123. Pharming Group Recent Developments
    Table 124. Protalix BioTherapeutics Company Details
    Table 125. Protalix BioTherapeutics Business Overview
    Table 126. Protalix BioTherapeutics Neurometabolic Disorders Product
    Table 127. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 128. Protalix BioTherapeutics Recent Developments
    Table 129. Amicus Company Details
    Table 130. Amicus Business Overview
    Table 131. Amicus Neurometabolic Disorders Product
    Table 132. Amicus Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 133. Amicus Recent Developments
    Table 134. Biomarin Company Details
    Table 135. Biomarin Business Overview
    Table 136. Biomarin Neurometabolic Disorders Product
    Table 137. Biomarin Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 138. Biomarin Recent Developments
    Table 139. Genzyme Company Details
    Table 140. Genzyme Business Overview
    Table 141. Genzyme Neurometabolic Disorders Product
    Table 142. Genzyme Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 143. Genzyme Recent Developments
    Table 144. Shire Company Details
    Table 145. Shire Business Overview
    Table 146. Shire Neurometabolic Disorders Product
    Table 147. Shire Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 148. Shire Recent Developments
    Table 149. Greencross Company Details
    Table 150. Greencross Business Overview
    Table 151. Greencross Neurometabolic Disorders Product
    Table 152. Greencross Revenue in Neurometabolic Disorders Business (2017-2022) & (US$ Million)
    Table 153. Greencross Recent Developments
    Table 154. Research Programs/Design for This Report
    Table 155. Key Data Information from Secondary Sources
    Table 156. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neurometabolic Disorders Market Share by Type: 2021 VS 2028
    Figure 2. Gaucher’s Disease Features
    Figure 3. Fabry Disease Features
    Figure 4. Pompe Disease Features
    Figure 5. Mucopolysaccharidosis VI Features
    Figure 6. Other Features
    Figure 7. Global Neurometabolic Disorders Market Share by Application: 2021 VS 2028
    Figure 8. Oral Case Studies
    Figure 9. Parenteral Case Studies
    Figure 10. Neurometabolic Disorders Report Years Considered
    Figure 11. Global Neurometabolic Disorders Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Neurometabolic Disorders Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Neurometabolic Disorders Market Share by Region: 2021 VS 2028
    Figure 14. Global Neurometabolic Disorders Market Share by Players in 2021
    Figure 15. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2021
    Figure 17. North America Neurometabolic Disorders Market Size YoY (2017-2028) & (US$ Million)
    Figure 18. North America Neurometabolic Disorders Market Size Market Share by Type (2017-2028)
    Figure 19. North America Neurometabolic Disorders Market Size Market Share by Application (2017-2028)
    Figure 20. North America Neurometabolic Disorders Market Size Share by Country (2017-2028)
    Figure 21. United States Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Neurometabolic Disorders Market Size YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Neurometabolic Disorders Market Size Market Share by Type (2017-2028)
    Figure 25. Europe Neurometabolic Disorders Market Size Market Share by Application (2017-2028)
    Figure 26. Europe Neurometabolic Disorders Market Size Share by Country (2017-2028)
    Figure 27. Germany Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Neurometabolic Disorders Market Size YoY (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Neurometabolic Disorders Market Size Market Share by Type (2017-2028)
    Figure 35. Asia Pacific Neurometabolic Disorders Market Size Market Share by Application (2017-2028)
    Figure 36. Asia Pacific Neurometabolic Disorders Market Size Share by Region (2017-2028)
    Figure 37. China Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Japan Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. South Korea Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. India Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Australia Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 43. Latin America Neurometabolic Disorders Market Size YoY (2017-2028) & (US$ Million)
    Figure 44. Latin America Neurometabolic Disorders Market Size Market Share by Type (2017-2028)
    Figure 45. Latin America Neurometabolic Disorders Market Size Market Share by Application (2017-2028)
    Figure 46. Latin America Neurometabolic Disorders Market Size Share by Country (2017-2028)
    Figure 47. Mexico Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Brazil Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Neurometabolic Disorders Market Size YoY (2017-2028) & (US$ Million)
    Figure 50. Middle East and Africa Neurometabolic Disorders Market Size Market Share by Type (2017-2028)
    Figure 51. Middle East and Africa Neurometabolic Disorders Market Size Market Share by Application (2017-2028)
    Figure 52. Middle East and Africa Neurometabolic Disorders Market Size Share by Country (2017-2028)
    Figure 53. Turkey Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. UAE Neurometabolic Disorders Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 57. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 58. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 59. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 60. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 61. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 62. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 63. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 64. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 65. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 66. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 67. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 68. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 69. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 70. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 71. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 72. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 73. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2017-2022)
    Figure 74. Bottom-up and Top-down Approaches for This Report
    Figure 75. Data Triangulation
    Figure 76. Key Executives Interviewed